The purpose of the study is 1) to study the safety and tolerability of escalating doses of myelin peptide reactive T cells in MS patients and 2) to study the clinical effectiveness of T Cell Vaccine ion the clinical course of MS.

The principle of TCV is similar to that of traditional microbial vaccination where attenuated infectious agents are used to stimulate protective immune responses. Because pathogentic autoreactive T cells are viewed as pathogens in T cell-mediated autoimmune diseases, they can be used, as a vaccine to prevent and treat the diseases in which they are able to induce.

Inclusion Criteria:

• Stable MS disease within 30 days prior to enrollment
• EDSS Score between 2 and 8 inclusively
• Failed to respond to or cannot tolerate at least 1 or more of the currently approved drugs for MS.

Exclusion Criteria:

• Women who are pregnant or breast-feeding or who plan to become pregnant during the study
• Has taken immunomodulating drugs within 60 days prior to screening
• HIV positive